Eva Amurri’s Biggest “Parenting Fail”

dnrt8765

Every parent has a moment they wish they could re-do, and for mom of 3 Eva Amurri, that moment happened when her oldest, daughter Marlowe, was 4 months old.

In a new interview with People the actress and blogger behind Happily Eva After recalls the moment when she experienced her “biggest parenting fail” and Marlowe “rolled off the changing table”.

A lot of parents can relate to this. It happens so much. According to the CDC, about 50% of nonfatal injuries in babies under a year old come from falls. Amurri is hardly the only parent to have this

Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update

dnrt8765

TORRANCE, Calif.–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the second quarter 2020 financial results and provided a general business update.

“We are very happy to have concluded the reverse merger on June 15th and in that process, brought on a very well-respected group of investors, including Alger, BVF Partners, Franklin Templeton and OrbiMed to support Forte as we continue to grow the company. Our lead program, FB-401, developed in collaboration with the National Institute of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has shown

Ask Amy: Worried mom puts the cart before the carrot – Lifestyle – providencejournal.com

dnrt8765

Dear Amy,

My daughter is in her 30s. Her boyfriend has decided to be totally vegan. She has decided to be vegan, too, which is fine. They’re adults and they will do what they believe is best.

My question concerns these new dietary restrictions.

At some point they may have children. I would like advice about whether being vegan is good for children in utero, and as they develop.

Is it healthy and advisable?

These kids will be in situations over their lives when traveling, at social situations, or during holidays where they may have to make eating choices that

Celcuity Reports Second Quarter 2020 Financial Results and Recent Business Highlights

dnrt8765

– Presented data for first CELsignia Pathway Activity Test for ovarian cancer at AACR Annual Meeting –

– Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020 –

– Cash burn rate steady –

– Cash and Cash Equivalents of $15.4 million as of June 30, 2020, which is expected to support operations through 2021 –

– Conference Call on Monday, August 10th at 4:30pm (ET) –

MINNEAPOLIS, MN / ACCESSWIRE / August 10, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into